← All trials
NCT04041349
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2019
- Primary completion
- Aug 31, 2020
- Completion date
- Sep 28, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Southern Medical UniversityLead sponsor
- Guangdong Pharmaceutical UniversityCollaborator
- Jinan UniversityCollaborator
- Shantou UniversityCollaborator
- Southern Medical UniversityOverall official - principal investigator
- Southern Medical UniversityReponsible party - principal investigator
- Guangzhou Medical UniversityCollaborator
- Wuhan UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Dongguan Houjie HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.